Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

P-AI-n or g-AI-n?

Who will win in an AI-coloured world?

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

Biogen Idec building

Biogen’s RoActemra biosimilar Tofidence approved by EC to treat arthritis and COVID-19

The regulator’s decision was supported by evidence demonstrating Tofidence’s similarity to the reference product

- PMLiVE

FDA approves argenx’s Vyvgart Hytrulo for rare neuromuscular disorder CIDP

Approximately 24,000 US patients are currently being treated for chronic inflammatory demyelinating polyneuropathy

- PMLiVE

New phase 2 study launched to evaluate triple drug combination in pancreatic cancer

The PRIMUS-006 study will evaluate Lilly/Genentech’s Gemzar in combination with Merck’s Keytruda and Immodulon’s IMM-101

- PMLiVE

ISID establishes six global infectious disease priorities to be addressed at 2024 congress

Involving health and community leaders, the ISID congress will commence in South Africa in December

- PMLiVE

Pharma’s content conundrum

With consistency problems, quantity and quality needs and HCP overload, it’s time to take content even more seriously

- PMLiVE

OPEN Health and fusion announce partnership to deliver AI-powered healthcare communications

OPEN Health, a pre-eminent global provider of scientific communications, HEOR and market access, patient engagement, and consulting, today announced a partnership with fusion, an innovative artificial intelligence (AI) and machine...

OPEN Health

- PMLiVE

Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

- PMLiVE

Bristol Myers Squibb’s Krazati granted FDA accelerated approval in colorectal cancer

More than 106,000 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Study reveals single copy of protective genetic variant delays early Alzheimer’s onset

Approximately 900,000 people in the UK are affected by dementia and Alzheimer’s is the most common form

- PMLiVE

Gilead shares positive phase 3 results for twice-yearly HIV PrEP drug in women

Lenacapavir demonstrated 100% efficacy in protecting more than 2,000 women against the infection

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links